AbCellera Biologics (ABCL) Depreciation & Amortization (CF) (2020 - 2026)

AbCellera Biologics has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $5.9 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 34.23% year-over-year to $5.9 million; the trailing twelve-month figure through Mar 2026 stood at $19.8 million (up 44.95% YoY), and the FY2025 full-year result was $18.4 million, up 47.2% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $5.9 million, up from $5.1 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $5.9 million in Q1 2026, with the low at $1.4 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $3.4 million across 5 years, with a median of $3.2 million in 2024.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) sank 46.53% — and 2025, when it soared 147.21%.
• AbCellera Biologics' Depreciation & Amortization (CF) stood at $2.7 million in 2022, then jumped by 40.75% to $3.9 million in 2023, then slumped by 46.53% to $2.1 million in 2024, then soared by 147.21% to $5.1 million in 2025, then advanced by 16.04% to $5.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $5.9 million (Q1 2026), $5.1 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.